Research & Development

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.

Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

The US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia (ITP).

Bristol Myers Squibb wraps up acquisition of MyoKardia

Bristol Myers Squibb (BMS) has completed the acquisition of clinical-stage biopharmaceutical company MyoKardia for $13.1bn.

Roche, Lead Pharma partner to develop oral small molecules for immune-mediated diseases

Lead Pharma has signed a collaboration and license agreement with Roche for the development of oral small molecules to treat a range of immune-mediated diseases.

Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis

Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of Lupin Limited (Lupin), announced today that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.

Medigen, BlueWillow collaborate to develop SARS-CoV-2 intranasal vaccine

Medigen Vaccine Biologics (MVC) has collaborated with BlueWillow Biologics for the development of intranasal vaccine for SARS-CoV-2, the novel coronavirus responsible for Covid-19 disease.

Pharmaron acquires Absorption Systems in US

Pharmaron Beijing, a fully integrated contract research and manufacturing organization offering laboratory, CMC and clinical development services for the life science industry, announced today that it has acquired 100% of the equity of Absorption Systems for up to $137.5m in cash.

Merck to buy biopharmaceutical firm VelosBio for $2.75bn

Merck has agreed to acquire US-based clinical-stage biopharmaceutical company VelosBio for $2.75bn in cash.

ACG buys significant stake in India’s CRO IQGEN-X

ACG, a provider of integrated pharmaceutical manufacturing solutions, has purchased a significant stake in India-based contract research organisation (CRO) IQGEN-X.